Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current …
I Mitani, D Jain, TM Joska, B Burtness… - Journal of nuclear …, 2003 - Elsevier
Background. Congestive heart failure (CHF) is among the most serious toxicities of
doxorubicin, a potent cancer chemotherapeutic agent. Serial left ventricular ejection fraction
(LVEF) monitoring during doxorubicin therapy for preventing CHF was proposed over 20
years ago. The current utility and cost-effectiveness of this approach in the present era are
not known. Methods and Results. Clinical and follow-up data of 265 patients with cancer
(age, 53±14 years; 76% women) undergoing doxorubicin chemotherapy with serial …
doxorubicin, a potent cancer chemotherapeutic agent. Serial left ventricular ejection fraction
(LVEF) monitoring during doxorubicin therapy for preventing CHF was proposed over 20
years ago. The current utility and cost-effectiveness of this approach in the present era are
not known. Methods and Results. Clinical and follow-up data of 265 patients with cancer
(age, 53±14 years; 76% women) undergoing doxorubicin chemotherapy with serial …